NFKB1 and hepatocellular carcinoma: MiR-16 is able to suppress HCC cell progression by targeting the immunogenic protein faint expression in normal tissues, aberrant overexpression in tumors (FEAT) and inhibiting epithelial-mesenchymal transition (EMT) and the nuclear factor-κB (NF-κB) [32].